A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination
- 30 May 2007
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 25 (22), 4437-4446
- https://doi.org/10.1016/j.vaccine.2007.03.028
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Brucella spp. lumazine synthase: a novel adjuvant and antigen delivery system to effectively induce oral immunityMicrobes and Infection, 2006
- A Polymeric Bacterial Protein Activates Dendritic Cells via TLR4The Journal of Immunology, 2006
- High Order Quaternary Arrangement Confers Increased Structural Stability to Brucella sp. Lumazine SynthasePublished by Elsevier BV ,2004
- Rough vaccines in animal brucellosis: Structural and genetic basis and present statusVeterinary Research, 2004
- BrucellaLumazine Synthase Elicits a Mixed Th1-Th2 Immune Response and Reduces Infection in Mice Challenged withBrucella abortus544 Independently of the Adjuvant Formulation UsedInfection and Immunity, 2003
- Molecular Host-Pathogen Interaction in Brucellosis: Current Understanding and Future Approaches to Vaccine Development for Mice and HumansClinical Microbiology Reviews, 2003
- A DNA Vaccine Encoding Lumazine Synthase fromBrucella abortusInduces Protective Immunity in BALB/c MiceInfection and Immunity, 2002
- An Overview of Human BrucellosisClinical Infectious Diseases, 1995
- Brucella melitensis Rev-1 vaccine as a cause of human brucellosisThe Lancet, 1993
- Epididymitis in Rams and LambsVeterinary Clinics of North America: Food Animal Practice, 1990